Literature DB >> 15737033

Usefulness of cutaneous T-cell clonality analysis for the diagnosis of cutaneous T-cell lymphoma in patients with erythroderma.

Nadege Cordel1, Bernard Lenormand, Philippe Courville, Marie France Helot, Jacques Benichou, Pascal Joly.   

Abstract

CONTEXT: Demonstration of a dominant T-cell clone in skin biopsy specimens by a molecular assay constitutes an additional diagnostic criterion to differentiate cutaneous T-cell lymphomas (CTCLs) from inflammatory dermatoses.
OBJECTIVE: To determine which patients, depending on their clinical presentations, could most benefit from a cutaneous T-cell clonality analysis in addition to histopathologic analysis for the diagnosis of CTCL.
DESIGN: Comparison of sensitivity and specificity of histopathologic analysis and a combination of this method and the detection of a T-cell receptor gamma chain gene rearrangement by polymerase chain reaction denaturing gradient gel electrophoresis performed on skin biopsy specimens obtained at initial presentation. PATIENTS: One hundred forty consecutive patients were classified into 4 groups, depending on their clinical presentation: (1) eczematous patches suggestive of early-stage mycosis fungoides (MF) (IA and IB of the TNM classification) (n = 42); (2) plaques, nodules, or tumors that arise on or are associated with plaques suggestive of late-stage MF (IIB and III of the TNM classification) (n = 16); (3) erythroderma (n = 50); and (4) nodules or tumors that arise in normal skin, suggestive of non-MF CTCL (n = 32).
RESULTS: When compared with histopathologic examination, the addition of clonality analysis increased the sensitivity of CTCL diagnosis in all groups of patients except those with cutaneous lesions suggestive of late-stage MF, because the diagnosis was made based on histopathologic analysis alone in 100% of these cases. The main increase in sensitivity of CTCL diagnosis was observed in patients with erythroderma: 62% with histopathologic analysis alone to 87% with the combination of both methods (P = .04). Diagnostic specificity of molecular assays decreased from 100% to 76% (P = .01) in patients with patch lesions and from 100% to 70% (P = .04) in patients with nodules that occurred in normal skin due to the detection of a T-cell clone in 6 patients with follicular mucinosis without a histologic pattern of MF and in 5 of 20 cases of T-cell pseudolymphoma (25%), respectively. In contrast, a T-cell clone was not detected in the 34 patients with erythroderma of inflammatory origin.
CONCLUSION: Polymerase chain reaction analysis of cutaneous T-cell clonality could be useful for the diagnosis of CTCL in patients who present with erythroderma.

Entities:  

Mesh:

Year:  2005        PMID: 15737033     DOI: 10.5858/2005-129-372-UOCTCA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

Review 1.  Mycosis fungoides and sezary syndrome: an update.

Authors:  Ellen J Kim; Julie Lin; Jacqueline M Junkins-Hopkins; Carmela C Vittorio; Alain H Rook
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

2.  Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis.

Authors:  Nadège Cordel; Benoît Tressières; Michel D'Incan; Laurent Machet; Florent Grange; Éric Estève; Sophie Dalac; Saskia Ingen-Housz-Oro; Martine Bagot; Marie Beylot-Barry; Pascal Joly
Journal:  Oncologist       Date:  2015-12-14

3.  Diagnostic Value of Genotypic Analysis in Primary Cutaneous Lymphomas using Standardized BIOMED-2 Polymerase Chain Reaction Protocols: Experience in Daily Clinical Practice.

Authors:  Daniel López Aventín; Fernando Gallardo; Luis Colomo; Ester Moragón; María Carmen Vela; Xavier Duran Jordà; Beatriz Bellosillo; Ramon M Pujol
Journal:  Acta Derm Venereol       Date:  2021-05-19       Impact factor: 3.875

4.  Erythroderma: a prospective study of 309 patients followed for 12 years in a tertiary center.

Authors:  Denis Miyashiro; José Antonio Sanches
Journal:  Sci Rep       Date:  2020-06-17       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.